

# PUBLIC ASSESSMENT REPORT of the Medicines Evaluation Board in the Netherlands

# Lachgas Yes 100% v/v, medicinal gas, liquefied Yes Pharmaceutical Development Services GmbH, Germany

# nitrous oxide

This assessment report is published by the MEB pursuant Article 21 (3) and (4) of Directive 2001/83/EC. The report comments on the registration dossier that was submitted to the MEB and its fellow –organisations in all concerned EU member states.

It reflects the scientific conclusion reached by the MEB and all concerned member states at the end of the evaluation process and provides a summary of the grounds for approval of a marketing authorisation.

This report is intended for all those involved with the safe and proper use of the medicinal product, i.e. healthcare professionals, patients and their family and carers. Some knowledge of medicines and diseases is expected of the latter category as the language in this report may be difficult for laymen to understand.

This assessment report shall be updated by a following addendum whenever new information becomes available.

General information on the Public Assessment Reports can be found on the website of the MEB.

To the best of the MEB's knowledge, this report does not contain any information that should not have been made available to the public. The MAH has checked this report for the absence of any confidential information.


# EU-procedure number: NL/H/2606/001/DC Registration number in the Netherlands: RVG 111763

# 25 June 2013

Pharmacotherapeutic group:
ATC code:
Route of administration:
Therapeutic indication:
Prescription status:
Date of authorisation in NL:
Concerned Member States:
Application type/legal basis:

Other general anesthetics N01AX13 inhalation (initiation of) anaesthesia; analgesia/sedation prescription only 16 April 2013 Decentralised procedure with BE, BG, DE, RO, SK Directive 2001/83/EC, Article 10a

For product information for healthcare professionals and users, including information on pack sizes and presentations, see Summary of Product Characteristics (SPC), package leaflet and labelling.



# I INTRODUCTION

Based on the review of the quality, safety and efficacy data, the member states have granted a marketing authorisation for Lachgas Yes 100% v/v, medicinal gas, liquefied from Yes Pharmaceutical Development Services GmbH. The date of authorisation was on 16 April 2013 in the Netherlands.

Nitrous oxide is indicated as a mixture with oxygen:

- in anaesthesia and/or for the initiation of anaesthesia. It is used as a basic anaesthetic in combination with inhalation anaesthetics (such as halothane, enflurane, isoflurane, sevoflurane, desflurane), intravenous anaesthetics (such as thiopental, propofol), opiates and/or muscle relaxants.
- for analgesia/sedation in all situations where pain relief/sedation of rapid onset and rapid offset are desirable.

Nitrous oxide is indicated for use in adults and children above the age of 1 month.

A comprehensive description of the indications and posology is given in the SPC.

Available data indicate that nitrous oxide has both direct and indirect effects on the transmission of a number of neurotransmitters both in the brain and the spinal cord. Its effect on the endorphin system throughout the CNS is presumably one of the more central mechanisms underlying the analgesic effects. Results have also shown that nitrous oxide affects noradrenaline activity in the posterior horn of the spinal cord and that to some extent its analgesic effects depend on spinal inhibition.


Nitrous oxide is a gas with strong analgesic and mild narcotic effects. Nitrous oxide has dose-dependent effects on sensory and cognitive functions that start at 15%. Concentrations exceeding 60-70% cause unconsciousness. Nitrous oxide has dose-dependent analgesic properties that are clinically perceptible at end-tidal concentrations around 20%.

Since the "Note for Guidance on medicinal gases: Pharmaceutical documentation" (CPMP/QWP/1719/00) was adopted in 2002, it is mandatory in the European Union to register medicinal gases as medicine replacing the status of medical device. Hence, a number of medicinal gases have now received a marketing authorisation.

The marketing authorisation is granted based on article 10a (well-established medicinal use) of Directive 2001/83/EC.

This application concerns a bibliographical application based on well-established medicinal use of nitrous oxide. This type of application does not require submission of the results of pre-clinical tests or clinical trials if the applicant can demonstrate that the active substance of the medicinal product has been in well-established medicinal use within the Community for at least 10 years, with recognised efficacy and an acceptable level of safety. "Medicinal use" does not exclusively mean "use as an authorised medicinal product", so that the proof of medicinal use may be submitted even in the absence of a marketing authorisation. Well-established use refers to the use for a specific therapeutic use. For this kind of application, a detailed description of the strategy used for the search of published literature and the justification for inclusion of the references in the application has to be provided. The documentation submitted by the applicant should cover all aspects of the assessment and must include a review of the relevant literature, taking into account pre- and post-marketing studies and published scientific literature concerning experience in the form of epidemiological studies and in particular of comparative epidemiological studies.

No scientific advice has been given to the MAH with respect to these products and no paediatric development programme has been submitted.



# II SCIENTIFIC OVERVIEW AND DISCUSSION

## II.1 Quality aspects

#### **Compliance with Good Manufacturing Practice**

The MEB has been assured that acceptable standards of GMP (see Directive 2003/94/EC) are in place for this product type at all sites responsible for the manufacturing of the active substance as well as for the manufacturing and assembly of this product prior to granting its national authorisation.

#### Active substance

The active substance is nitrous oxide, an established active substance, described in the European Pharmacopoeia (Ph.Eur.\*). It is a colourless gas with a slightly sweet smell, which is only slightly perceptible. It is heavier than air and non-flammable in air.

#### Manufacturing process

Nitrous oxide is produced by thermal decomposition of ammonium nitrate:  $NH_4NO_3 \rightarrow N_2O + 2 H_2O$ . The purified nitrous oxide is then compressed, dried and liquefied. The liquefied gas is transferred to a refrigerated storage tank. This is the general process to manufacture nitrous oxide which is also the basis of the Ph.Eur. monograph. Information on suppliers of starting material, specifications of reagents, and inprocess controls have been provided.

## Quality control of drug substance

The drug substance specification is in line with the Ph.Eur.; this specification is acceptable. The process at all production sites is deemed sufficiently under control. Compliance with Ph.Eur. requirements is confirmed by batch analysis data.

#### Stability of drug substance

The drug substance is packaged in insulated containers dedicated for the storage of nitrous oxide. No stability studies have been undertaken. This is acceptable as nitrous oxide is a well-known, stable gas. A retest period is not applicable.

\* Ph.Eur. is an official handbook (pharmacopoeia) in which methods of analysis with specifications for substances are laid down by the authorities of the EU.

# Medicinal Product

#### Composition


Lachgas Yes 100% v/v is a colourless gas with slightly sweet taste and smell. Nitrous oxide is also colourless in its liquefied form.

The product consists of 100% nitrous oxide v/v in seamless steel or aluminium cylinders of various capacities and in cylinder bundles.

No excipients are present.

#### Pharmaceutical development

Manufacturing and assembly of Nitrous oxide YES 100% medicinal gas, liquefied utilises a wellestablished method that has been used for a number of years in Europe for the production of relevant medicinal products. The manufacturing process of the drug product consists exclusively of the refilling process of the active substance into cylinders, which in turn can be used independently by the end users. The cylinders, bundling frames and valves are in compliance with ADR standards (European Agreement concerning the International Carriage of Dangerous Goods by Road), as well as the "Guideline on Medicinal Gases" (CPMP/QWP/1719/00 Rev 1), which requires that cylinders and valves must bear CE markings.



All valves were brought into accordance with EU Council Directive 1999/36/EC. Compatibility of cylinder and valve materials is standardised in EN ISO 11114-1:1997 for metallic materials and in EN-ISO 11114-2:2000 for non-metallic materials. The packaging is usual for this type of product.

The product is supplied as a non-sterile dosage form. Although no microbiological test and limits are specified for the finished product it is evident that nitrous oxide in liquid form during manufacture and in compressed/liquefied form after filling will not promote microbial growth. Pressurised cylinders will not permit the ingress of microbes into the primary container during its storage and use. The development is acceptable.

### Manufacturing process

The manufacturing process consists of filling nitrous oxide into cylinders. All operations are carried out in a closed circuit by means of a network of pipes with valves that are gas-specific and reserved solely for the nitrous oxide filling. This straightforward filling process has been described in sufficient detail. Adequate in-process controls are applied. Validation data have been provided for all manufacturing sites.

### Quality control of drug product

The product specification comprises the Ph Eur tests and requirements and additional tests for appearance of the cylinders, filling weight tolerance, labelling and pressure. Testing is performed as described in the current version of the European Pharmacopoeia monograph "Nitrous oxide".

Batch analysis data have been provided, confirming compliance with the proposed release requirements.

# Stability of drug product

The product is packaged in gas cylinders complying with current regulations. The approved shelf-life is 3 years under the conditions as described in section 6.4 of the SPC. No stability studies have been undertaken. This is acceptable as nitrous oxide is a well-known, stable gas.

<u>Specific measures concerning the prevention of the transmission of animal spongiform encephalopathies</u> There are no substances of ruminant animal origin present in the product nor have any been used in the manufacturing of this product, so a theoretical risk of transmitting TSE can be excluded.

# **II.2** Non-clinical aspects

Nitrous oxide has been available on the European market for several decades. A non-clinical overview on the pharmacology, pharmacokinetics and toxicology has been provided, which is based on up-to-date and adequate scientific literature. The overview justifies why there is no need to generate additional non-clinical pharmacology, pharmacokinetics and toxicology data. Therefore, the member states agreed that no further non-clinical studies are required.

#### **Environmental risk assessment**

No environmental risk assessment has been performed, which is acceptable for this application.

# II.3 Clinical aspects


To support this application, the MAH submitted an expert report with a literature review. No new clinical studies were performed for this application. This is acceptable, since the current application concerns a product that is essentially similar to those already on the market in the Netherlands.

#### Pharmacokinetics

Nitrous oxide is transported in blood as free gas; it does not bind to hemoglobin. As hypoxia may occur due to dilution effect in the alveoli, N2O is always mixed with oxygen at clinical use (50-70% N2O/O2).

Nitrous oxide is not metabolized by enzymes, but it is washed-out by exhalation. No PK interactions at enzyme level are expected, as nitrous oxide is not metabolized by enzymes. No accumulation is expected in renal or hepatic patients, or children.

# Pharmacodynamics



N2O is a weak anaesthetic (minimum alveolar concentration - MAC around 105%) and analgesic, that may need combination with other substances, in particular for general anaesthesia. The equivalent analgesic effect of N2O in an adult patient has been estimated to require around 10-15 mg of morphine.

The underlying mechanisms of N2O-induced analgesic effects have been partly elucidated. It has been suggested in the literature that endogenous opioid peptide release, and inhibition of GABA-ergic and glutamate-mediated excitatory neurotransmission, may play a role.

## Clinical efficacy

The use of nitrous oxide at induction and maintenance of anaesthesia, in a 70%/30% N2O/O2 mixture, is well-established. N2O cannot provide sufficient level of anaesthesia on its own, but is combined with more potent other anaesthetics (e.g. inhalation anaesthetics, propofol, opioids). N2O is mainly used in anaesthesia for its analgesic properties. It reduces the need of other anaesthetics significantly, contributing to better tolerability of anaesthesia, as inhalational anaesthetic agents may be cardiotoxic, hepatotoxic, or increase cerebral flow and intra-cranial pressure. The benefits are that the use of N2O shortens induction of anaesthesia, and reduces the needs op opioids and other anesthetics at induction and maintenance. It also appears to reduce retrograde amnesia.

However, N2O causes Post-Operative Nausea and Vomiting. According to the ENIGMA trial, N2O as adjuvant in maintenance of general anesthesia may even be associated with enhanced perioperative cardiovascular (CV) risks and wound infection, although confounding was not excluded, as there were differences in depth of anesthesia and O2 use between N2O arm and control. Recently, a prospective trial in 1773 patients undergoing carotid surgery did not confirm an enhanced CV risk. (GALA trial, Sanders et., 2012)<sup>1</sup>.

The safety and efficacy of this commonly used inhalant anesthetic is under discussion among anesthesiologists. There is no general European guideline available on the use of N2O in general anesthesia. However, there is still a place for N2O in European practice, as a part of as analgesic component in 'balanced anaesthesia' add-on to other anaesthetic drugs, and because of its well-established safety record, or low costs. There are advantages of the use of nitrous oxide in renal or hepatic compromised patients, as there is no accumulation in these special patients.

Nitrous oxide, as 50/50 N2O/O2 mixture is a strong analgesic drug, which is well established and can be safely used in labor and a broad range of painful procedures. It has a rapid onset and off-set of effect. It is also anxiolytic. It is as effective as other drugs commonly used in painful procedures (midazolam, propofol), but with lower sedation rate.


# **Clinical safety**

The safety profile of nitrous oxide depends on the clinical context where it is used, and dose and duration of exposure.

At short-term use in procedural pain and labor, at a 50%/50% N2O/O2 mixture, nitrous oxide is in general well tolerated. Nausea and neuropsychiatric events are commonly reported, but severe cases are rare. N2O at short term use in labor in low doses (50%) is not harmful for the fetus and neonate.

Nitrous oxide, as used in general anaesthesia at higher doses (70%/30% N2O/O2), is associated with a higher risk of Post-Operative Nausea/Vomiting (PONV) compared to placebo. Recently, N2O at maintenance of anaesthesia is discussed, as it may be associated with wound infections and cardiovascular risk, as reported in the ENIGMA trial, a RCT in about 2000 subjects. Especially patients with enhanced homocysteine plasma levels, as a signal of vitamin B12 depletion, may be at risk. However, any cardiovascular risk of N2O is not confirmed by another recent study in 1773 carotid surgery patients (GALA trial).

<sup>&</sup>lt;sup>1</sup> Sanders RD, Graham C, Lewis SC, Bodenham A, Gough MJ, Warlow C; GALA Trial Investigators. Br J Anaesth. 2012 Sep;109(3):361-7. Epub 2012 Jun 17.



Long-term exposure to nitrous oxide is associated with vitamin B12 depletion, and consecutively megaloblastic anemia and spinal cord damage, or, in pregnant women, neural tube closure disorders. Probably as it has opioid effects, nitrous oxide has an abuse/addition potential. Health care professionals and patients need to be protected against long term exposure. Adequate warnings and measures are proposed in the SPC.

Nitrous oxide can be safely used in special populations like children, renal and hepatic patients. As there is a lack of clinical data of the use of N2O in neonates, and this age group may be more vulnerable to vitamin B12 depletion and neurotoxicity, the use in this age group is not recommended.

### Pharmacovigilance plan

The pharmacovigilance system as described by the MAH fulfils the requirements and provides adequate evidence that the MAH has the services of a qualified person responsible for pharmacovigilance and has the necessary means for the notification of any adverse reaction suspected of occurring either in the Community or in a third country.

### Risk minimisation plan

On the basis of the safety specification and considering the extensive clinical experience, the MAH does not consider it necessary to establish specific risk minimisation activities. Routine risk minimisation activities, such as warnings included in the product information and a careful labelling and packaging should be adequate for avoiding the risks that may be associated with this product. No additional risk minimisation activities (such as educational material or training programmes for prescribers, pharmacists and patients, restricted access programmes) will be required.

# **Product information**

### <u>SPC</u>

The content of the SPC approved during the decentralised procedure is adequate. Health care professionals and patients need to be protected against long term exposure. Adequate warnings and measures are included in the SPC.

# Readability test

The package leaflet has been evaluated via a user consultation study in accordance with the requirements of Articles 59(3) and 61(1) of Directive 2001/83/EC. The test consisted of a pilot test, followed by two rounds with 10 participants each. The majority of questions were answered without any significant problems. Overall, more than the required 90% (i.e. 18 out of 20 respondents) were able to find the requested information and thereof more than the required 90% were able to understand it. The readability test has been sufficiently performed.



# III OVERALL CONCLUSION AND BENEFIT-RISK ASSESSMENT

The use of nitrous oxide at lower doses as analgesic and anxiolytic drug is well established, and has a good safety record. Also the use as an analgesic component in general anaesthesia is well established; Although there are some concerns about higher risk of post-operative nausea/vomiting and potential risk of CV events, the latter is not confirmed in some studies. Other analgesics used in general anaesthesia, like opioids, may cause nausea as well, or have longer carry-over effect post-operative.

Nitrous oxide has the advantage that it can be used in renal and hepatic patients, without dose adjustments. The use in children is well-established, except in neonates, where data are sparse. Therefore, neonates are excluded from the indication.

The MAH has provided written confirmation that systems and services are in place to ensure compliance with their pharmacovigilance obligations.


The SPC, package leaflet and labelling contain adequate information and warnings, and are in the agreed templates.

The Board followed the advice of the assessors.

There was no discussion in the CMD(h). Agreement between member states was reached during a written procedure. The member states, on the basis of the data submitted, considered that Lachgas Yes 100% v/v demonstrated adequate evidence of efficacy for the approved indications as well as a satisfactory risk/benefit profile and therefore granted a marketing authorisation. The decentralised procedure was finished on 28 February 2013. Lachgas Yes 100% v/v, medicinal gas, liquefied is authorised in the Netherlands on 16 April 2013.

The date for the first renewal will be: 28 February 2018.

There were no post-approval commitments made during the procedure.



# List of abbreviations

ASMF	Active Substance Master File
ATC	Anatomical Therapeutic Chemical classification
AUC	Area Under the Curve
BP	British Pharmacopoeia
CEP	Certificate of Suitability to the monographs of the European Pharmacopoeia
CHMP	Committee for Medicinal Products for Human Use
CI	Confidence Interval
C <sub>max</sub>	Maximum plasma concentration
CMD(h)	Coordination group for Mutual recognition and Decentralised procedure for human medicinal products
CV	Coefficient of Variation
EDMF	European Drug Master File
EDQM	European Directorate for the Quality of Medicines
EU	European Union
GCP	Good Clinical Practice
GLP	Good Laboratory Practice
GMP	Good Manufacturing Practice
ICH	International Conference of Harmonisation
MAH	Marketing Authorisation Holder
MEB	Medicines Evaluation Board in the Netherlands
OTC	Over The Counter (to be supplied without prescription)
PAR	Public Assessment Report
Ph.Eur.	European Pharmacopoeia
PIL	Package Leaflet
PSUR	Periodic Safety Update Report
SD	Standard Deviation
SPC	Summary of Product Characteristics
t <sub>1/2</sub>	Half-life
t <sub>max</sub>	Time for maximum concentration
TSE	Transmissible Spongiform Encephalopathy
USP	Pharmacopoeia in the United States



# STEPS TAKEN AFTER THE FINALISATION OF THE INITIAL PROCEDURE - SUMMARY

Scope	Procedure number	Type of modification	Date of start of the procedure	Date of end of the procedure	Approval/ non approval	Assessment report attached